Company Encyclopedia
View More
name
Kenvue
KVUE.US
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
491.81 B
KVUE.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
C
Personal Care ProductsIndustry
Industry Ranking18/53
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE13.47%B
    • Profit Margin9.55%B
    • Gross Margin59.35%A
  • Growth ScoreC
    • Revenue YoY-2.93%D
    • Net Profit YoY34.68%B
    • Total Assets YoY1.20%C
    • Net Assets YoY-0.09%C
  • Cash ScoreC
    • Cash Flow Margin1047.17%B
    • OCF YoY-2.93%D
  • Operating ScoreC
    • Turnover0.55C
  • Debt ScoreD
    • Gearing Ratio60.97%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    COO Stevens Acquires 660 Of Kenvue Inc [KVUE]

    Stevens Meredith, COO of Kenvue Inc [KVUE], filed a Form 4 on November 20, 2025, disclosing the exercise and surrender of 660 shares at $14.37 each, valued at $9,484. Ending holdings are 64,441 shares directly. The surrender was to cover option exercise costs and/or tax liabilities.

    Reuters·
    US
    KVUE
    +1.15%
    Reuters·
    US
    KVUE
    +1.15%

    Kenvue Inc. Stock Falls Wednesday, Underperforms Market

    Kenvue Inc. (KVUE) shares fell 1.05% to $16.06 on Wednesday, marking the fourth consecutive day of losses. Despite a positive trading session for the broader market, Kenvue's stock underperformed, closing 36.19% below its 52-week high of $25.17. Trading volume was 30.5 million, below the 50-day average of 41.6 million.

    Dow Jones·
    US
    KVUE
    +1.15%
    Dow Jones·
    US
    KVUE
    +1.15%

    Jefferies Sticks to Their Buy Rating for Kenvue, Inc. (KVUE)

    Jefferies analyst Keith Devas maintained a Buy rating for Kenvue, Inc. (KVUE) with a price target of $23.00. Devas has an average return of -10.4% and a 30.77% success rate. Kenvue, Inc. has a consensus rating of Moderate Buy with a price target consensus of $19.42.

    Tip Ranks·
    US
    KVUE
    +1.15%
    Tip Ranks·
    US
    KVUE
    +1.15%

    Kennedy’s junk science puts Tylenol — and Trump — on Trial

    Texas Attorney General Ken Paxton has filed a lawsuit against Tylenol makers, alleging a debunked link between the drug and autism, echoing claims by HHS Secretary Robert F. Kennedy Jr. This legal action, tied to Kennedy's connections with personal injury firms, challenges President Trump's agenda. The lawsuit, part of a broader campaign against Tylenol, is criticized for undermining science-based health policies and eroding public trust in health institutions. Kennedy's actions are seen as aligning with trial lawyers rather than public health interests, potentially leading to more legal battles for Trump.

    Thehill·
    US
    KVUE
    +1.15%
    Thehill·
    US
    KVUE
    +1.15%

    Kenvue, Inc.: Hold Rating Amid Legal Uncertainties and Market Volatility

    Citi analyst Filippo Falorni maintains a Hold rating on Kenvue, Inc. with a price target of $18.00, citing legal uncertainties from the MDL case on acetaminophen affecting stock performance. Recent court hearings favoring plaintiffs led to a drop in KVUE's stock price. Barclays also maintains a Hold rating with the same price target, reflecting cautious investor sentiment amid ongoing legal proceedings.

    Tip Ranks·
    US
    KVUE
    +1.15%
    Tip Ranks·
    US
    KVUE
    +1.15%